ヒグチ　トモアキ   Higuchi Tomoaki   樋口　智昭    所属   医学部 医学科（東京女子医科大学病院）    職種   寄附部門講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis.
掲載誌名	正式名：Modern rheumatology 略　 称：Mod Rheumatol ISSNコード：14397609/14397595
巻・号・頁	pp.-
著者・共著者	Watanabe Ryu, Oshima Megumi, Nishioka Norihiro, Sada Ken-Ei, Nagasaka Kenji, Akiyama Mitsuhiro, Ando Taiki, Higuchi Tomoaki, Inoue Yoshino, Kida Takashi, Mutoh Tomoyuki, Nakabayashi Akihiko, Onishi Akira, Sakai Ryota, Waki Daisuke, Yamada Yosuke, Yajima Nobuyuki, Tamura Naoto, Kaname Shinya, Harigai Masayoshi
発行年月	2022/09/16
概要	OBJECTIVES:To provide evidence for the revision of clinical practice guidelines for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis by the Japan Research Committee for Intractable Vasculitis.METHODS:PubMed, CENTRAL, and the Japan Medical Abstracts Society databases were searched for articles published between 2015 and 2020 to update the systematic review for existing clinical questions, while PubMed, CENTRAL, EMBASE, and the Japan Medical Abstracts Society were searched for articles published between 2000 and 2020 to conduct a systematic review for newly developed clinical questions. The certainty of evidence was assessed with the GRADE approach.RESULTS:For remission induction, when used in conjunction with cyclophosphamide or rituximab, reduced-dose glucocorticoid lowered the risk of serious adverse events compared to standard-dose glucocorticoid. Avacopan improved sustained remission at 12 months compared to high-dose glucocorticoid. Addition of plasma exchange to remission induction therapy did not reduce the risk of death, end-stage kidney disease, or relapse. For remission maintenance, rituximab reduced the risk of relapse compared to azathioprine. Long-term rituximab or azathioprine reduced the risk of relapse compared to short-term rituximab or azathioprine, respectively.CONCLUSION:This systematic review provided evidence required to develop the 2023 clinical practice guideline for the management of ANCA-associated vasculitis.
DOI	10.1093/mr/roac114
PMID	36112482